• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.

    5/8/26 11:21:38 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 20)


    Tarsus Pharmaceuticals, Inc.

    (Name of Issuer)


    Common

    (Title of Class of Securities)




    87650L103

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    87650L103


    1Names of Reporting Persons

    PRUDENTIAL FINANCIAL INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,670,648.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,836,321.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,836,321.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Tarsus Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    15440 LAGUNA CANYON ROAD, IRVINE, CALIFORNIA, 92618.
    Item 2. 
    (a)Name of person filing:

    Prudential Financial, Inc.
    (b)Address or principal business office or, if none, residence:

    751 Broad Street Newark, New Jersey 07102-3777
    (c)Citizenship:

    New Jersey
    (d)Title of class of securities:

    Common
    (e)CUSIP No.:

    87650L103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,836,321.00
    (b)Percent of class:

    4.3  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    1,670,648.00

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    1,836,321.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Prudential Financial, Inc. is a Parent Holding Company and the indirect parent of the following subsidiaries, who are the beneficial owners of the number and percentage of securities which are the subject of this filing as set forth next to their names: Subsidiaries Number of shares Percentage Jennison Associates LLC IA 1,712,124.00 4.0 The Prudential Insurance Company of America IC 117,972 0.3 PGIM Quantitative Solutions LLC IA 6,225.00 0.0
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PRUDENTIAL FINANCIAL INC
     
    Signature:/s/ Danny Fiore
    Name/Title:Second Vice President
    Date:05/08/2026
    Get the next $TARS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TARS

    DatePrice TargetRatingAnalyst
    4/24/2026$105.00 → $98.00Outperform
    Oppenheimer
    12/9/2025$100.00Overweight
    Barclays
    11/20/2025$100.00Outperform
    Mizuho
    6/2/2025$75.00Outperform
    Oppenheimer
    5/27/2025$72.00Buy
    H.C. Wainwright
    11/20/2023$19.00Neutral
    Goldman
    7/18/2023$44.00Outperform
    William Blair
    5/18/2023Buy
    Guggenheim
    More analyst ratings

    $TARS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

    IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor. Since joining Tarsus in 2021, Ms. Clase has played an integral role in the Company's evolution from a clinical-stage organization to a successful commercial biopharmaceutical company with one of the best launches in eye care to date. H

    7/13/26 4:05:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

    IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near-term path forward; transaction structured to align economics with future value creation Tarsus to host investor conference call today, July 8, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the poten

    7/8/26 4:05:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

    SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat

    6/2/26 8:30:00 AM ET
    $ACHV
    $MANE
    $TARS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $TARS
    SEC Filings

    View All

    Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

    8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)

    7/13/26 4:11:59 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)

    7/8/26 4:13:40 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tarsus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)

    6/29/26 4:19:53 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Goldberg Andrew D. bought $18,960 worth of shares (1,000 units at $18.96), increasing direct ownership by 50% to 3,000 units (SEC Form 4)

    4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

    12/19/23 6:30:59 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Tarsus Pharmaceuticals with a new price target

    Oppenheimer resumed coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $98.00 from $105.00 previously

    4/24/26 8:29:40 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Tarsus Pharmaceuticals with a new price target

    Barclays initiated coverage of Tarsus Pharmaceuticals with a rating of Overweight and set a new price target of $100.00

    12/9/25 8:53:51 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Tarsus Pharmaceuticals with a new price target

    Mizuho initiated coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $100.00

    11/20/25 8:08:27 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

    Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:35:13 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

    Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

    7/25/23 4:29:16 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Chaudhuri Bhaskar

    4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

    6/29/26 4:31:27 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Morrison Scott W

    4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

    6/29/26 4:31:40 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Goldberg Andrew D.

    4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

    6/29/26 4:31:52 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARS
    Financials

    Live finance-specific insights

    View All

    Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

    IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care Positive Phase 2b/3 data and an FDA-aligned Phase 3 program provide a clear and near-term path forward; transaction structured to align economics with future value creation Tarsus to host investor conference call today, July 8, 2026, at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the poten

    7/8/26 4:05:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

    Generated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85% year-over-year Reaffirmed full-year 2026 guidance of $670-700 million of XDEMVY net product sales and peak sales potential exceeding $2 billion Nearly half of core eye care professionals are prescribing XDEMVY weekly, driven by deeper utilization, increased patient demand through Direct-to-Consumer campaign, and ongoing evidence generation Initiated Calliope, a Phase 2 trial of TP-05, a novel investigational oral tablet for the potential prevention of Lyme disease, with topline data expected in the first half of 2027 Management to host conference call today, May 6, 2026, at 1:30 p.m.

    5/6/26 4:05:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

    IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to ad

    4/29/26 4:30:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARS
    Leadership Updates

    Live Leadership Updates

    View All

    Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

    IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor. Since joining Tarsus in 2021, Ms. Clase has played an integral role in the Company's evolution from a clinical-stage organization to a successful commercial biopharmaceutical company with one of the best launches in eye care to date. H

    7/13/26 4:05:00 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

    IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. "David is one of the most accomplished leaders in eye care, with a strong track record of translating innovation into global impact," said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. "His experience building some of the most successful franchises in our industry will be invaluable as we scale XDEMVY, advance our pipeline and position Tarsus for sustained growth. We are honored

    2/18/26 8:30:00 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

    Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access

    11/13/24 8:30:00 AM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TARS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

    SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    11/14/24 4:41:12 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

    SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    11/14/24 4:35:55 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

    SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

    11/14/24 3:05:35 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care